Abstract : Propofol is a short-acting intravenous anesthetic agent. Dexmedetomidine, a highly selective 2 -adrenergic receptor agonist, has a well-known sedative effect. Both agents exhibit cytoprotective effects in the nervous system under ischemic conditions. Recently, the combination of propofol plus dexmedetomidine was used for the sedation of mechanically ventilated patients in an intensive care unit, but there are few experimental reports of the protective effects of the propofol plus dexmedetomidine combination in cells. Meanwhile, intraoperative brain ischemia-reperfusion induces endoplasmic reticulum ER stress-mediated apoptosis. The aim of the present study was to clarify molecular details underlying the neuroprotection afforded by the combination of propofol plus dexmedetomidine against thapsigargin TG -induced ER stress in human neuroblastoma SH-SY5Y cells, and whether the combination provided more ef cient neuroprotection. TG was used to generate ER stress in SH-SY5Y cells. Cells were pretreated with propofol or dexmedetomidine, individually or in combination, for 1 h before cotreatment with TG for 20 h. There was a signi cant increase in Ca 2 i , caspase activation, and the expression of ER stress biomarkers in TG-induced apoptotic cells. The increase in Ca 2 i and the induction of ER stress by TG were suppressed by pretreatment with propofol, dexmedetomidine, and their combination. The dexmedetomidineinduced reduction in caspase activity and ER stress biomarkers was inhibited by pretreatment with an 2 -adrenergic receptor antagonist, but was enhanced by pretreatment with a cAMP inhibitor. Treatment with the propofol plus dexmedetomidine combination exhibited the strongest protection against TG-induced apoptosis. These results demonstrate that the combination of propofol plus dexmedetomidine at clinically relevant concentrations suppresses ER stress-induced apoptosis in neuroblastoma SH-SY5Y cells. The ndings suggest that the combination of propofol plus dexmedetomidine within a clinically relevant concentration range may be used safely in patients.
Introduction
The 2013 Clinical Practice Guideline For Management of Pain, Agitation and Delirium in Adult Patients in Intensive Care Unit 1 recommends the use of non-benzodiazepinebased sedation and adequate analgesia to prevent agitation and delirium. Propofol and dexmedetomidine are known to produce less agitation and delirium. As agitation and delirium are associated with mortality and many adverse events, they must be prevented 2 . Strategies to reduce the unwanted effects of anesthetic agents are important. Propofol, a GABA A receptor agonist, is a short-acting intravenous anesthetic agent that is used for anesthesia and sedation but has no analgesic action. It is the preferred sedative in intensive care units ICU because it offers advantages over benzodiazepines in terms of lack of accumulation, rapid onset, and rapid recovery after withdrawal. Reported adverse effects of propofol include hypotension, bradycardia, respiratory depression, and hypertriglyceridemia 3 .
Furthermore, because prolonged use of high-dose propofol causes propofol infusion syndrome PRIS , the prolonged use of high-dose propofol should be avoided 3 .
As propofol does not have any analgesic action, combination with an adjuvant to provide analgesia is required. Furthermore, propofol has been reported to exhibit dose-dependent cardiodepressive effects 4 . Thus, propofol is commonly used in combination with other drugs that provide adequate analgesia 5 .
Dexmedetomidine is a highly selective 2 -adrenergic receptor agonist with both sedative and analgesic properties that is devoid of respiratory depressant effects 6 . Dexmedetomidine is an alternative to GABA receptor agonists for use as a sedative in the ICU. In addition to producing sedation, dexmedetomidine reduces concurrent analgesic requirements while maintaining a patient s arousability and not compromising respiratory drive 7 . Propofol and dexmedetomidine produce less agitation and delirium compared with benzodiazepines, so the combination of propofol plus dexmedetomidine is used in the ICU to maintain spontaneous respiration while providing adequate sedation. Several studies have reported that dexmedetomidine infusion significantly reduces propofol requirements during the induction and maintenance of general anesthesia 8 . In addition, there are many reports that propofol has neuroprotective effects against trauma and under ischemic conditions 9, 10 , and we have reported that propofol has neuroprotective effects against endoplasmic reticulum ER stress-mediated apoptosis 11 . In addition to its well-proven sedative effects, dexmedetomidine has been shown to exert cellprotective effects in nervous tissue under ischemic conditions 12 . Recently, the combination of propofol plus dexmedetomidine has been used to sedate mechanically ventilated patients in the ICU 13 . However, the relative benefits, and potential harm, of using these two drugs remain controversial. Furthermore, few experiments have investigated the neuroprotective effects of the combination of propofol plus dexmedetomidine in cells. Intraoperative brain ischemia-reperfusion causes ER stress, decreasing glucose, energy, and ER Ca 2 availability, eventually leading to the induction of apoptosis. Insults such as ischemia or hypoxia not only induce changes in the respiratory, circulatory, and nervous systems in the entire body, but they also damage individual cells. Ischemia after surgery causes ER stress and leads to rapid activation of the unfolded protein response UPR 14 .
The aim of the present study was to clarify the molecular mechanisms underlying the neuroprotection afforded by the combination of propofol plus dexmedetomidine against thapsigargin TG -induced ER stress in human neuroblastoma SH-SY5Y cells, and to determine whether the combination provides more efficient neuroprotection.
Materials and methods

Drugs and reagents
Propofol 2,6-diisopropylphenol , dexmedetomidine 5-1S -1-2,3-dimethylphenyl ethyl -1H-imidazole, hydrochloride , TG, Dulbecco s modified Eagle s medium DMEM and Ham s F-12 were purchased from Wako Pure Chemical Industries Osaka, Japan . Fetal bovine serum FBS , atipamezole and 2 ,5 -dideoxyadenosine ddAdo were purchased from Sigma-Aldrich St. Louis, MO, USA . Antibiotic-antimycotic penicillin G, streptomycin, amphotericin B were obtained from Life Technologies Carlsbad, CA, USA . All other chemicals used in the present study were of the purest grade available commercially. 15 and prolonged exposure of the cells to TG will induce apoptosis. In addition, we have reported previously that ER stress is induced in SH-SY5Y cells following treatment with 1 µM TG 11 . In the present study, cells were pretreated with propofol 1, 5, 10 µM or dexmedetomidine 1, 10, 100, 1000 nM , individually or in combination prop dex , for 1 h before cotreatment with 1 µM TG for a further 20 h. In some experiments, cells were incubated with the 2 -adrenergic receptor antagonist atipamezole 0.3 µM or the adenylyl cyclase inhibitor ddAdo 100 µM for 10 min prior to treatment with propofol, dexmedetomidine, or prop dex. All treatments were performed under sterile conditions.
Caspase-3 and -4 activities
Caspase-3 and -4 activity was determined fluorometrically using respective synthetic peptide substrates. SH-SY5Y cells that had been pretreated with propofol 1, 5, 10 µM , dexmedetomidine 1, 10, 100, 1000 nM , or prop dex for 1 h before incubation with TG for another 20 h were rinsed with cold phosphate-buffered saline PBS , resuspended in chilled cell lysis buffer Cell Signaling Technology, Danvers, MA, USA , and incubated on ice for 10 min. Then, after incubation, reaction buffer containing 10 µM dithiothreitol Medical & Biological Laboratories, Aichi, Japan and the respective specific peptide substrate were added to each sample, and incubated at 37 for 2 h. The substrates used for caspase-3 Kamiya Biochemical, Seattle, WA, USA and caspase-4 BioVision Technology, Chester Springs, PA, USA were Asp-Glu-Val-Asp-7-amino-4-trifluoromethyl coumarin DEVD-AFC and Leu-Glu-Ala-Asp-AFC LEVD-AFC , respectively. The AFC released by the enzyme reaction was measured spectrophotometrically at excitation and emission wavelengths of 405 and 505 nm, respectively, on a Spectra Max 340i3 Molecular Devices, Sunnyvale, CA, USA . Protein content was determined using the Bio-Rad Protein Assay with bovine serum albumin BSA as the standard.
Determination of C / EBP homologous protein
After 20 h exposure to TG following 1 h pretreatment with propofol 1 µM , dexmedetomidine 1, 10, 100 nM , or prop dex, cells were extracted with a cold cell lysis buffer and sonicated using an ultrasonic cell disrupter. For quantitative determination of C / EBP homologous protein CHOP in SH-SY5Y cell lysates, an ELISA kit for DNA damage inducible transcript 3 CHOP ; Uscn Life Science, Wuhan, China was used.
Eukaryotic translation-initiation factor 2 phosphorylation
Phosphorylation of eukaryotic translation-initiation factor 2 eIF2 was evaluated using an eIF2 ELISA kit Cell Signaling Technology according to the manufacturer s instructions. SH-SY5Y cells 1 10 6 cells / ml were pretreated with propofol 1 µM , dexmedetomidine 1, 10, 100 nM , or prop dex for 1 h, followed by 20 h exposure to TG. Cells were fixed and blocked as directed by the manufacturer, and incubated with anti-phosphorylated p-eIF2 Thr 183 / Tyr 185 or anti-eIF2 , which are included in the kit. Cells were then examined spectrophotometrically at 405 nm with a Spectra Max 340pc Molecular Devices .
Determination of cAMP levels
Concentrations of cAMP were determined using a Cyclic AMP ELISA kit Cayman Chemical, Ann Arbor, MI, USA according to the manufacturer s instructions. SH-SY5Y cells were pretreated with propofol 1 µM , dexmedetomidine 1, 10, 100 nM , or prop dex for 1 h, followed by 20 h exposure to TG. In addition, in some experiments, SH-SY5Y cells were preincubated with atipamezole for 10 min before pretreatment with propofol or dexmedetomidine, after which cAMP levels were determined using the ELISA kit according to the manufacturer s instructions.
Determination of Ca 2 i
Ca 2 i levels were evaluated using a FLIPR Calcium 5 Assay Kit Molecular Devices . In these studies, SH-SY5Y cells were loaded with FLIPR reagent diluted in Hank s balanced salt solution 20 mM HEPES buffer pH 7.4 for 1 h at 37 . After SH-SY5Y cells had been incubated with the FLIPR reagent, changes in Ca 
Statistical analysis
All measurements were repeated three times. Results are expressed as the mean SEM. The effects of various treatments were compared with untreated control cells using one-way analysis of variance ANOVA and post hoc Dunnett s test. P 0.05 was considered significant.
Results
Effects of propofol and dexmedetomidine on caspase-3 activity
TG-induced ER stress-mediated apoptosis was detected by determining caspase-3 activity Fig. 1 . In SH-SY5Y cells, there was no significant effect on caspase-3 activity following incubation of cells with either 1 and 5 µM propofol or 1, 10, and 100 nM dexmedetomidine. However, when cells were incubated with 10 µM propofol or 1000 nM dexmedetomidine, caspase-3 activity increased significantly compared with activity in untreated SH-SY5Y cells Fig.  1A . After 20 h incubation with TG, caspase-3 activity increased significantly in SH-SY5Y cells compared with untreated control cells. Pretreatment of SH-SY5Y cells with propofol 1, 5 µM or dexmedetomidine 1, 10, 100 nM before 20 h exposure to TG significantly suppressed the TG-induced increase in caspase-3 activity. These observations indicate that propofol or dexmedetomidine can inhibit TG-induced apoptosis, but that a high concentration of dexmedetomidine 1000 nM can itself induce ER stress-induced apoptosis. The effects of dexmedetomidine can be inhibited by the highly specific 2 -adrenergic receptor antagonist atipamezole 16 . In the present study, pretreatment of SH-SY5Y cells with atipamezole prior to exposure of cells to 10 nM dexmedetomidine and TG significantly increased caspase-3 activity compared with TG dexmedetomidine 10 nM treatment Fig. 1B . These findings support the notion that the protective effect of dexmedetomidine against ER stress-induced apoptosis is mediated through 2 -adrenergic receptors. Under TG-induced ER stress, there was a tendency for greater suppression of caspase-3 activity with prop dex 10 nM compared with propofol or dexmedetomidine treatment alone, but the differences did not reach statistical significance Fig. 1C .
Effects of propofol and dexmedetomidine on TG-induced ER stress
Caspase-4 activity Fig. 2 shows changes in caspase-4 activity in SH-SY5Y cells. TG significantly increased caspase-4 activity, and this increase was significantly suppressed by both propofol 1 µM , similar to previous findings 10 , and dexmedetomidine 1, 10, 100 nM . When SH-SY5Y cells were pretreated with atipamezole prior to exposure to dexmedetomidine 10 nM and TG, caspase-4 activity was significantly increased Fig. 2A . Under TG-induced ER stress, treatment with prop dex 10 nM had a greater inhibitory effect on TG-induced increases in caspase-4 activity than treatment with either propofol or dexmedetomidine alone Fig. 2B . Fig. 3 shows changes in CHOP levels in SH-SY5Y cells. TG significantly increased CHOP levels in SH-SY5Y cells, and this was significantly suppressed by propofol 1 µM and dexmedetomidine 1, 10, 100 nM pretreatment. Under TG-induced ER stress, prop dex treatment resulted in a greater reduction in TG-induced increases in CHOP levels than treatment with either propofol or dexmedetomidine 10 nM alone. Incubation of cells with atipamezole before exposure to dexmedetomidine 10 nM and TG significantly increased CHOP levels. Fig. 4 . shows phosphorylation of eIF2 in SH-SY5Y cells. Phosphorylation of eIF2 was significantly increased in TG-treated cells, and this was significantly suppressed by propofol, dexmedetomidine, and prop dex pretreatment. Under TG-induced ER stress, prop dex treatment resulted in a greater reduction in TG-induced increases in ER stress compared with either propofol or dexmedetomidine 10 nM alone. When cells were incubated with atipamezole before being exposed to dexmedetomidine 10 nM and TG, eIF2 phosphorylation increased significantly to levels seen following exposure to TG alone Fig. 4 .
CHOP levels
eIF2 phosphorylation
Effects of propofol and dexmedetomidine on intracellular cAMP
Dexmedetomidine binds to 2 -adrenergic receptors, which are coupled to Gi-proteins, inhibiting adenylyl cyclase activity and downregulating cAMP formation 17 . In this series of experiments we investigated whether cAMP is involved in the protective effects of dexmedetomidine against TG-induced ER stress-induced apoptosis. Pretreatment with dexmedetomidine 10, 100 nM significantly decreased cAMP levels in SH-SY5Y cells exposed to TG. When cells were treated with atipamezole before being exposed to dexmedetomidine 10 nM and TG, cAMP levels increased significantly compared with values in the dexmedetomidine plus TG-treated group Fig.  5 . Because propofol did not alter cAMP levels, the results suggest that cAMP is not involved in the protective effects of propofol.
Effects of propofol and dexmedetomidine on TG-induced increases in Ca 2 i
Meta Xpress Images Acquisition was used in the present study to investigate the effects of propofol, dexmedetomidine, and prop dex pretreatment on Ca 2 i in SH-SY5Y cells exposed to TG. In TG-treated cells Ca 2 i levels were increased, and increased levels were maintained over the 180 s of analysis. In contrast, propofol, dexmedetomidine, and prop dex pretreatment 6 . In a previous study we found that propofol treatment significantly inhibited the effects of TG from the early phase 11 , and we speculate that in the present study propofol inhibited the TG-induced release of Ca 
Discussion
In the present study we showed that the combination of propofol plus dexmedetomidine suppressed ER stress-mediated apoptosis of SH-SY5Y cells. When SH-SY5Y cells were treated with prop dex, ER stress-mediated apoptosis was suppressed to a greater extent than that seen after treatment with propofol or dexmedetomidine alone. In particular, the combination of 1 µM propofol plus 10 nM dexmedetomidine had the strongest neuroprotective effects.
Typically, patients receive 1-2.5 mg / kg propofol as an intravenous bolus injection for the induction of general anesthesia. When a target control infusion TCI pump is used, the target plasma concentration for maintenance of propofol anesthesia is usually between 2.0 and 5.0 µg / ml. However, propofol binds extensively to plasma protein mean bound : 97 -98 , with 50 being bound to erythrocytes and 48 binding to serum proteins, almost exclusively to human serum albumin. The free fraction of propofol in the blood is in the range 1.2 -1.7
at total concentrations ranging from 0.5 to 32 µg / ml 18 .
If dexmedetomidine is administrated by a loading dose followed by infusion at a rate of 0.2-0.83 µg / kg per h, patients in this setting could obtain an effective dexmedetomidine concentration of 0.22-2.50 ng / ml 1.1-12.5 nM . Furthermore, plasma dexmedetomidine concentrations are moderately correlated with the dose administered 19 .
Therefore, the concentrations of propofol 1 µM and dexmedetomidine 10 nM used in the present study are similar to serum concentrations seen used clinically. On this basis, it is speculated that the combination of 1 µM propofol plus 10 nM dexmedetomidine may exhibit neuroprotective effects in the clinical setting.
TG decreased Ca concentration in the ER is reduced, there is an increase in misfolded proteins, causing ER stress. The adaptive response to ER stress is the UPR. When the UPR process works normally, the overloading with abnormal proteins in the ER is reduced and the cell can adapt to the insult. However, after excessively severe insults, cells cannot adapt and apoptosis is induced via ER stress.
ER stress can be induced by several different situations, including ischemia-reperfusion and trauma, as well as by many neurodegenerative diseases, so there are many benefits to suppressing ER stress. In a previous study we found that TG treatment was able to generate ER stress 11 , thus we decided that the use of TG was the most appropriate way to induce ER stress in the present study. Propofol is widely used as an intravenous anesthetic and sedative agent. In a previous study, human glioblastoma cells were treated with 300-500 µM propofol 20 . In that study, increases in Ca 2 i were observed and the authors reported that propofol induced apoptosis in dosedependent manner within 24 h 20 . In another study, human promyelocytic leukemia cells were treated with 150-250 µM propofol and, after 5 h, activation of caspase-3, as an indicator of apoptosis, was observed 21 . However, treatment with propofol at a clinically relevant concentration shows neuroprotective effects. Propofol protects nerve, pulmonary epithelial, vascular endothelial, and kidney cells [22] [23] [24] . We have reported previously that 5 µM propofol suppresses ER stress-induced apoptosis by inhibiting Ca 2 release from the ER 11 .
Dexmedetomidine is a potent and highly selective agonist of 2 -adrenergic receptors in the human brain, and its effects include clinical sedation, anesthetic-sparing effects, and analgesia 25 .
Recent studies have indicated that dexmedetomidine also exhibits neuroprotective effects against ischemic injury 26 and promotes the survival of nervous tissue that has suffered traumatic injury 27 . However, a study in neutrophils reported that treatment with a high concentration of dexmedetomidine 100 ng / ml ; 499.3 nM accelerated apoptosis, whereas a clinically relevant concentration of dexmedetomidine 1 ng / ml ; 4.993 nM did not affect neutrophil apoptosis 28 .
In the present study of ER stress-mediated apoptosis, dexmedetomidine 10, 100 nM exhibited neuroprotective effects. Moreover, we have demonstrated in the present study that pretreatment with 10 nM dexmedetomidine significantly decreased the TG-stimulated increase in Ca 2 i . Pre-incubation of cells with the membrane-permeable adenylyl cyclase inhibitor ddAdo 100 µM further suppressed Ca 2 i levels in cells treated with dexmedetomidine plus TG Fig. 6 . The neuroprotective actions of dexmedetomidine have largely been attributed to its effect as an agonist at 2 -adrenergic receptors 29, 30 .
The 2 -adrenergic receptor is coupled to a Gi-protein complex, which inhibits adenylyl cyclase and Ca 2 channels. The result of 2 -adrenergic receptor agonist binding is a reduction in cAMP production and decreased Ca 2 i
31 . Under ER stress, dexmedetomidine 10, 100 nM treatment significantly decreased cAMP levels Fig. 5 . Agonist stimulation of postsynaptic 2 -adrenergic receptors mediates the sedative and analgesic effects of dexmedetomidine 32 . The neuroprotective actions of dexmedetomidine in ER stress-mediated apoptosis have also been attributed to its effect as an agonist at 2 -adrenergic receptors.
In the present study, treatment with the prop dex combination at a clinically relevant concentration showed the strongest neuroprotective effect against TG-induced ER stress-mediated apoptosis. As mentioned above, the neuroprotective effect of the prop dex combination against ER stress-mediated apoptosis is caused by a reduction in Ca 2 i : that is, propofol inhibits Ca 2 release from the ER 10 , whereas dexmedetomidine binds to 2 -adrenergic receptors, thus decreasing intracellular cAMP levels. Structurally, dexmedetomidine is an imidazole derivative, and it binds not only to 2 -adrenergic receptors, but also to imidazoline receptors 33 . Therefore, it is necessary to determine whether the neuroprotective effects of dexmedetomidine are mediated via imidazoline receptors in addition to 2 -adrenergic receptors. Further detailed studies are needed to determine how the combination of propofol plus dexmedetomidine provides neuroprotection. The combination of propofol plus dexmedetomidine is useable because it means that the dose of propofol, which has respiratory suppressive effects and may cause PRIS, can be reduced while maintaining adequate sedation levels. However, the findings of the present study cannot be extrapolated to humans without further in vitro studies that provide further evidence that the combination of propofol plus dexmedetomidine is able to protect nerve tissue under the situations that cause ER stress, such as ischemia-reperfusion, trauma, and neurodegenerative diseases.
In conclusion, the present study has demonstrated that the combination of propofol plus dexmedetomidine has a strong protective effect against ER stress-mediated apoptosis in SH-SY5Y cells. The neuroprotective effect of the propofol plus dexmedetomidine combination is mediated by propofol inhibition of Ca 
